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ABSTRACT: Older age and cardiovascular comorbidities are well-known risk factors for all-cause mortality in patients with 
coronavirus disease 2019 (COVID-19). Hypertension and age are the 2 principal determinants of arterial stiffness (AS). This 
study aimed to estimate AS in patients with COVID-19 requiring hospitalization and analyze its association with all-cause in-
hospital mortality. This observational, retrospective, multicenter cohort study analyzed 12 170 patients admitted to 150 Spanish 
centers included in the SEMI-COVID-19 Network. We compared AS, defined as pulse pressure ≥60 mm Hg, and clinical 
characteristics between survivors and nonsurvivors. Mean age was 67.5 (±16.1) years and 42.5% were women. Overall, 2606 
(21.4%) subjects died. Admission systolic blood pressure (BP) <120 and ≥140 mm Hg was a predictor of higher all-cause 
mortality (23.5% and 22.8%, respectively, P<0.001), compared with systolic BP between 120 and 140 mm Hg (18.6%). The 
4379 patients with AS (36.0%) were older and had higher systolic and lower diastolic BP. Multivariate analysis showed that 
AS and systolic BP <120 mm Hg significantly and independently predicted all-cause in-hospital mortality (adjusted odds 
ratio [ORadj]: 1.27, P=0.0001; ORadj: 1.48, P=0.0001, respectively) after adjusting for sex (males, ORadj: 1.6, P=0.0001), 
age tertiles (second and third tertiles, ORadj: 2.0 and 4.7, P=0.0001), Charlson Comorbidity Index (second and third tertiles, 
ORadj: 4.8 and 8.6, P=0.0001), heart failure, and previous and in-hospital antihypertensive treatment. Our data show that AS 
and admission systolic BP <120 mm Hg had independent prognostic value for all-cause mortality in patients with COVID-19 
requiring hospitalization. (Hypertension. 2021;77:856–867. DOI: 10.1161/HYPERTENSIONAHA.120.16563.) 
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The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has emerged as a worldwide pandemic of unexpected 
severity. Initial symptoms usually affect the respiratory 
system and include fever, cough, and hypoxia. However, 
there is growing evidence that COVID-19 is actually a 
classic multisystem disease with a plethora of different 
signs and symptoms, among which cardiovascular mani-
festations predominate.1
Of the epidemiological connections between COVID-
19 and the arterial system, 3 are the most notable. First, 
hypertension invariably ranks in first place among base-
line comorbidities in patients with COVID-19.2 Second, 
although data are scarce and controversial,3 hyperten-
sion seems to represent an independent and significant 
determinant of all-cause mortality in patients hospital-
ized with COVID-19.4 Third, age is indisputably the risk 
factor most strongly associated with worse outcomes in 
patients with COVID-19.5 Long before the COVID-19 
pandemic began, arterial stiffness (AS) was a concept 
that unified the long-term impact of these 2 components 
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was originally interpreted as a marker of changes in the 
aortic wall and was thought to reflect underlying arterio-
sclerosis on multiple levels.6 Obesity, diabetes, smoking, 
and especially subclinical inflammation have been linked 
to pathological AS, but the 2 main determinants of AS 
are blood pressure (BP) and age, leading to the asser-
tion that AS should be recognized as the best marker 
of vascular aging.7 Current guidelines for the manage-
ment of hypertension include AS among the many tools 
for assessing hypertension-mediated organ damage 
because it has shown independent prognostic value 
beyond the commonly used risk tables.8
Carotid-femoral pulse wave velocity by applanation 
tonometry is the gold standard for measuring large-
artery stiffness.9 Although several techniques have been 
developed in recent years to estimate AS on a population 
scale,10 daily use of pulse wave velocity measurement 
requires training and time and is, therefore, not recom-
mended for routine practice. A practical, simple, and 
proven alternative approach to estimate the burden of 
AS in large populations is the calculation of pulse pres-
sure (PP; systolic BP−diastolic BP). Values above 60 
mm Hg have been shown to correlate significantly with 
AS, especially in older people, and its use as marker of 
AS is widely endorsed in the literature.11,12
We hypothesize that AS would be pathologically 
increased in patients with COVID-19 because they share 
the 2 principal risk factors: old age and hypertension. The 
objective of this study is to estimate AS by calculating the 
PP of patients with COVID-19 requiring hospital admis-
sion and analyze its association with all-cause mortality. 
The secondary objective is to characterize patients with 
AS who are included in the Spanish Society of Internal 
Medicine (SEMI)-COVID-19 Network database.
MATERIAL AND METHODS
Study Design and Population
Our study is based on the SEMI-COVID-19 Registry, an ongo-
ing multicenter, nationwide, observational cohort database 
in which 150 hospitals in all 17 regions of Spain participate. 
Further information on the registry and its data collection meth-
ods can be found in the source article.13 The data that support 
the findings of this study are available from the corresponding 
author upon reasonable request. Inclusion criteria for the reg-
istry were age ≥18 years and first admission to a hospital in 
Spain with diagnosis of COVID-19 confirmed microbiologically 
by reverse transcription polymerase chain reaction testing of a 
nasopharyngeal sample, following the recommendations of the 
World Health Organization. The exclusion criteria were declin-
ing to participate, withdrawal of informed consent, or subse-
quent admissions of the same patient. Patients were admitted 
and treated according to the clinical judgment of the attending 
physicians, following local protocols and the recommendations 
of the Spanish Ministry of Health. Personal data management 
strictly complied with Spanish Law 14/2007, of July 3, on 
Biomedical Research and Regulation (EU) 2016/679 of the 
European Parliament and with the Council of April 27, 2016, 
on the protection of natural persons with regard to the pro-
cessing of personal data and on the free movement of such 
data. The SEMI-COVID-19 Registry has been approved by 
the Provincial Research Ethics Committee of Malaga (Spain), 
following the recommendation of the Spanish Agency of 
Medicines and Medical Products (AEMPS, for its initials in 
Spanish). All the patients gave informed consent. From March 
1 to June 24, 2020, when the last patient was included in this 
substudy, 13 121 consecutive patients aged between 18 and 
106 years were recruited.
Hypertension was included among the list of variables 
recorded, along with previous and in-hospital use of ACE 
(angiotensin-converting enzyme) inhibitors and ARBs (angio-
tensin receptor blockers).
Nonstandard Abbreviation and Acronyms
ACE angiotensin-converting enzyme
ARB angiotensin receptor blocker
AS arterial stiffness
BP blood pressure





• Arterial stiffness, estimated as admission pulse pres-
sure ≥60 mm Hg, was associated with higher risk for 
all-cause mortality in patients hospitalized with corona-
virus disease 2019 (COVID-19).
What Is Relevant?
• This association was independent of other comorbidi-
ties, gender, age, and the presence of hypertension or 
antihypertensive treatment.
Summary
Elevated pulse pressure and blood pressure values 
<120 mm Hg at admission contribute independently to 
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Procedures
At least one physician from the internal medicine department 
in each hospital is voluntarily in charge of collecting and enter-
ing patients’ data from their medical record in an online elec-
tronic data capture system developed by the Spanish Society 
of Internal Medicine (SEMI, for its initials in Spanish). A data-
base manager (Dr Ramos Rincón) centrally verifies procedures 
and incoming data from all hospitals. An independent external 
agency together with the study’s scientific steering commit-
tee is responsible for database monitoring. Dissociated patient 
identifiable data are pseudo-anonymized to avoid direct identi-
fiers. All information is fully encrypted through a valid Transport 
Layer Security certificate and hosted on a secure server.
The database includes almost 300 variables under the fol-
lowing headings: (1) inclusion criteria; (2) epidemiological data; 
(3) reverse transcription polymerase chain reaction and serol-
ogy data; (4) personal medical and medication history, includ-
ing antihypertensive treatment, categorized as ACEIs, ARBs, 
or others; (5) symptoms and physical examination findings at 
admission; (6) laboratory (blood gases, metabolic panel, com-
plete blood count, coagulation) and diagnostic imaging tests; 
(7) additional data at seven days after admission or at admis-
sion to the intensive care unit; (8) pharmacological treatment 
during the hospitalization and ventilator support; (9) complica-
tions during the hospitalization; and (10) progress after dis-
charge and 30 days from diagnosis. The age-adjusted Charlson 
Comorbidity Index was calculated from the data collected.14 A 
complete list of variables can be found in the source article.13 
The primary end point was all-cause in-hospital mortality ver-
sus hospital discharge. The time of follow-up was defined as 
the period from admission to discharge or death. Mortality is 
expressed as the case fatality rate.
Statistical Analysis
Continuous variables were tested for normal distribution using 
Kolmogorov-Smirnov test. Results are shown as means (SD) or 
medians (25th–75th percentile) for continuous variables and 
absolute values (%) for categorical variables.
To compare baseline demographic and clinical character-
istics among the different groups, we used ANOVA or the 
Kruskal–Wallis test for continuous variables. Differences 
in proportion were analyzed using the χ2 test. Systolic BP 
(SBP) was divided into 3 categories: SBP <120 mm Hg, SBP 
≥120 and simultaneously SBP <140 mm Hg, and SBP ≥140 
mm Hg. The middle range group will be noted as 120≤ SBP 
<140. Hypertension was categorized as absent or present, 
and the latter was further subcategorized into 3 groups based 
on treatment received: (1) no ACEIs/ARBs, (2) ACEIs, and 
(3) ARBs. AS was defined as present when PP (systolic minus 
diastolic BP) was ≥60 mm Hg. The association between AS 
and death was analyzed using Kaplan-Meier survival curves; 
the log-rank test was calculated from baseline to time of 
death according to the presence or absence of AS. We used a 
logistic regression to evaluate the relationship between signif-
icant variables found on the univariate analysis and all-cause 
mortality; variables with P<0.1 on the univariate analysis were 
included. All statistical analyses were performed using SPSS 
software (IBM SPSS Statistics for Windows, Version 26.0. 
Armonk, NY: IBM Corp). A 2-tailed P<0.05 was considered 
statistically significant.
RESULTS
Demographic Characteristics of the Study 
Population
A total of 13 121 records were collected in the SEMI-
COVID-19 Registry at June 24, 2020, of which 951 were 
excluded due to missing information on certain key vari-
ables. A total of 12 170 (92.8%) subjects were included 
in this substudy, as can be seen in the patient flowchart in 
Figure 1. Table 1 includes the baseline demographic and 
clinical features of all participants and according to the 
presence or absence of AS. The mean age of the total 
group was 67.5±16.1 years and 42.5% were women. The 
vast majority of patients were White (90.0%), followed by 
patients of Latin American origin (8.2%). The data pre-
sented only include patients who were hospitalized and 
either discharged or died: 72.7% were discharged home, 
Figure 1. Patient inclusion flow chart.
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5.9% continued their recovery in health care institutions 
outside the hospitals, and 21.4% died. This proportion of 
deaths is consistent with official data from the Spanish 
Ministry of Health as of May 29, 2020 (20 534 deaths 
among 99 808 hospitalized patients, 20.6%).15 The most 
prevalent terminal complications of patients with COVID-
19 with fatal outcome was adult respiratory distress syn-
drome (76.8%), followed at a considerable distance by 
acute renal failure (36.0%), multiorgan failure (26.6%), 
secondary bacterial pneumonia (22.1%), sepsis (20.1%), 
shock (15.9%), heart failure (HF, 14.7%), and cardiac 
arrhythmia (9.3%). Disseminated intravascular (3.4%), 
myocarditis (2.5%), acute coronary disease (2.3%), pul-
monary embolism (1.9%), and stroke (1.7%) were also 
present but far more rare.
As shown in Table 1, hypertension was the most fre-
quent comorbidity (50.9%) in patients with COVID-19, 
followed by diabetes (19.1%), atrial fibrillation (11.1%), 
coronary heart disease (7.9%), stroke (7.7%), heart fail-
ure (HF; 7.1%), chronic obstructive pulmonary disease 
(COPD; 7.0%), chronic kidney disease (CKD; 6.0%), 
and peripheral arterial disease (4.7%). After sorting the 
population by presence or absence of AS, the data show 
that age, SBP and the Charlson Comorbidity Index score 
were markedly higher and diastolic BP lower in the for-
mer group compared with the latter. All the comorbidities 
analyzed were, without exception, far more frequent in 
patients with AS. We found small albeit significant differ-
ences in certain laboratory parameters.
Outcomes
Kaplan-Meier survival curves (Figure 2) according to 
presence or absence of AS confirm increased all-cause 
mortality in subjects with AS compared with those with-
out AS (log-rank P<0.001). A noteworthy finding is that 
Table 1. Demographic and Baseline Clinical Features of the Study Population in General and 




Arterial stiffness  
(yes; N=4379)
Arterial stiffness  
(no; N=7791) P value
Anthropomorphic measures
 Age, y 67.5±16.1 72.8±14.2 64.5±16.3 0.0001
 Women, % 42.5 43.7 41.9 NS
 Height, cm 165.3±9.5 164.3±9.2 165.8±9.7 0.0010
 Weight, kg 78.5±16.5 78.2±16.0 78.7±16.7 NS
 Obesity (BMI >30 kg/m2), % 21.3 23.0 20.4 0.0020
Blood pressure and selected laboratory values
 Systolic BP, mm Hg 129±21.0 146±18.1 119±15.2 0.0001
 Diastolic BP, mm Hg 74±12.8 70±13.9 75±13.3 0.0001
 Heart rate, bpm 88±17.3 73±13.1 75±12.7 0.0001
 Pulse pressure, mm Hg 55±19.8 74±13.2 44±9.3 0.0001
 Glycemia, mg/dL* 112 (98–136) 116 (100–143) 110 (97–131) 0.0011
 Creatinine, mg/dL* 0.8 (0.68–1.05) 0.9 (0.70–1.12) 0.8 (0.67–1.01) 0.0012
 Sodium, mg/dL 138±4.8 138±4.8 138±4.7 NS
 Potassium, mg/dL 4.1±0.6 4.2±0.58 4.1±0.55 0.0015
 Triglycerides, mg/dL* 121 (94–158) 123 (96–157) 120 (92–158) NS
Comorbidities
 Hypertension, % 50.9 62.0 44.7 0.0001
 Diabetes, % 19.1 24.2 16.2 0.0001
 COPD, % 7.0 8.2 6.3 0.0001
 CKD, % 6.0 7.7 5.1 0.0001
 Coronary heart disease, % 7.9 9.8 6.9 0.0001
 Heart failure, % 7.1 8.6 6.3 0.0001
 Stroke, % 7.7 9.6 6.7 0.0001
 Atrial fibrillation, % 11.1 13.2 9.9 0.0001
 Peripheral vascular disease, % 4.7 5.8 4.0 0.0001
 Charlson Comorbidity Index 3.6±2.7 4.3±2.6 3.2±2.6 0.0001
Values are average (SD). BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; and COPD, chronic 
obstructive pulmonary disease.
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the difference in survival can be detected from the very 
beginning, and the rate shows a tendency to converge at 
the end of the observation period.
Given the marked differences in SBP according to the 
presence/absence of AS, we focused on the association 
between all-cause in-hospital mortality, SBP, and AS. A 
graphical representation of the findings can be seen in 
Figure 3. The lowest mortality rate was found in patients 
with SBP between 120 and 140 mm Hg while worse 
outcomes significantly increased when SBP was below 
120 or exceeded 140 mm Hg (black columns), resem-
bling a J-curve phenomenon. No significant differences 
were found between the group of patients with SBP 
<120 and SBP ≥140 mm Hg. When dividing each SBP 
category into 2 groups according to PP <60 mm Hg 
(horizontally striped bars) or PP ≥60 mm Hg (diagonally 
striped bars), it is observed that patients with AS con-
stantly presented with a significantly higher all-cause 
mortality than those with PP <60 mm Hg across all 3 BP 
categories. In other words, within each BP group PP ≥60 
mm Hg was always associated with higher mortality than 
PP <60 mm Hg.
All-Cause in-Hospital Mortality According to 
Selected Variables
Table 2 analyzes the baseline differences between sur-
vivors and nonsurvivors. It shows that nonsurvivors were 
older; predominantly male; more fragile; and with a 
higher proportion of previous chronic diseases, especially 
hypertension but also AS. Paradoxically, no significant 
difference was detected in SBP, but diastolic BP was 
decreased and PP increased in nonsurvivors. Again, sig-
nificant differences in selected laboratory variables were 
observed, especially in glycemia, but they were small dif-
ferences and likely of little clinical relevance.
Subsequently, we performed a multivariate stepwise 
logistic regression analysis using all covariates with a 
significant (P<0.1) association with all-cause mortality as 
dependent variables (Table 3). The 2 main factors inde-
pendently predicting death were the Charlson Comorbid-
ity Index score and age. Male sex and HF were significant 
determinants; atrial fibrillation and CKD had a borderline 
significance (P=0.057 and P=0.070, respectively); and 
diabetes, COPD, and peripheral arterial disease were not 
significant and thus were not included in the multivari-
ate equation. In terms of BP-related variables, treatment 
of preexisting hypertension continued to be an indepen-
dently significant risk factor and ACEIs and ARBs as in-
hospital antihypertensive treatment remained variables 
with a beneficial predictive value. Likewise, presence of 
AS and BP below 120 mm Hg, as compared with BP 
between 120 and 140 mm Hg, represented significant 
deleterious risk factors. Interestingly, BP >140 mm Hg 
was found to be a protective factor, in contrast to what 
was found on the univariate analysis. We performed 2 
further sensitivity analyses. First, we defined BP either as 
below or above 120 mm Hg. In this case, AS (odds ratio, 
Figure 2. Kaplan-Meier curves 
in patients with/without arterial 
stiffness (AS).
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1.16 [CI, 1.03–1.31], P=0.01) and BP <120 (odds ratio, 
1.54 [CI, 1.36–1.75], P=0.001) continued to be signifi-
cant independent predictors of poor outcomes. Second, 
removing AS from the equation, BP <120 continued 
to be as a risk factor (odds ratio, 1.36 [CI, 1.21–1.54], 
P=0.001) and BP >140 ceased to have any protective 
effect (odds ratio, 0.92 [CI, 0.81–1.03], P=0.16). In other 
words, SBP >140 was protective only when simultane-
ously adjusting for PP. BP values below 120 mm Hg 
were a consistent predictor of worse outcomes whereas 
BP values >140 mm Hg were only significant depending 
on the presence of AS.
DISCUSSION
To the best of our knowledge, this retrospective, multi-
center cohort study represents one of the largest analy-
sis of hospitalized, treated, and discharged patients with 
COVID-19 worldwide. We analyzed data on 12 170 
patients with COVID-19 in 150 hospitals across Spain, 
obtaining a representative sample of the pandemic in our 
country. The most salient conclusion that can be drawn 
from our analysis is that pathological AS, estimated as 
PP ≥60 mm Hg at admission, can be interpreted as a 
deleterious risk factor with predictive value for all-cause 
in-hospital mortality in patients with COVID-19. This 
risk factor acts in addition to parameters that have been 
previously well-established as risk factors, such as age, 
fragility, sex, hypertension, and HF.4 It should be under-
scored that previous and in-hospital antihypertensive 
treatments were equally and simultaneously accounted 
for in this analysis and did not alter the conclusions; the 
former would seem to indicate that preexisting hyper-
tension does act together with AS as an independent 
risk factor and the latter suggesting that treatment with 
either ACEIs/ARBs during the hospital stay improves 
outcomes by significantly decreasing all-cause mortality.
Data concerning admission BP in patients with 
COVID-19 are very scarce and are included, at best, 
as minor pieces of data in larger predictive scores. Two 
recent studies found an association between worse out-
comes and low BP16,17 and 2 others found an associa-
tion between worse outcomes and high BP.18,19 However, 
none focused on the capital importance of BP per se. 
Furthermore, to date, this is the first study linking the 
severity of the COVID-19 pandemic to a marker of AS, 
namely PP ≥60 mm Hg. The limited availability of pulse 
wave velocity measurement capabilities in specialized 
Figure 3. All-cause in-hospital mortality according to systolic blood pressure (SBP) at hospital admission and presence (pulse 
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centers and the acuteness of COVID-19 cases during 
admission might explain why associations between AS 
and COVID-19 are lacking in the literature. Nonetheless, 
there is a plethora of evidence supporting the use of 
increased PP as a suitable surrogate marker of AS from 
before the COVID-19 pandemic20 and prospective works 
that include measuring pulse wave velocity in patients 
with COVID-19 have recently been launched.21
The starting point of our analysis was the observa-
tion that the relationship between all-cause in-hospi-
tal mortality and SBP in our patients with COVID-19 
resembled a J-curve phenomenon. Optimal BP targets 
in hypertension are a controversial matter, with some 
studies favoring the principle of the lower the bet-
ter,22 while others support the existence of a J-curve 
in regards to BP and outcomes.23,24 In fact, the optimal 
range of admission BP observed in our study endorses 
the latest recommendations found in recent guidelines: 
a BP between 120 and 140 mm Hg.25 Our analytical 
approach analyzed 3 BP categories (BP <120; 120≤ 
BP <140, and BP ≥140 mm Hg) and a PP threshold 
of ≥60 mm Hg. SBP <120 and ≥140 mm Hg reflected 
worse outcomes when compared with 120≤ SBP <140 
mm Hg. Adjusting each group according to the presence 
of AS revealed that higher PP was robustly associated 
with increased mortality across all 3 SBP groups. Due 
to the fact that patients with SBP ≥140 and PP <60 
mm Hg, who presented the lowest mortality rate of all 
patients, were numerically more frequent than those 
with AS, SBP ≥140 was found to be a protective fac-
tor on the multivariate analysis. In other words, higher 
SBP values were markers of increased risk only when 
PP ≥60 mm Hg. This observation is not surprising and 
physiologically understandable, given the fact that PP 










 Age, y 67.5±16.1 79.7±10.5 64.1±15.7 0.0001
 Women, % 42.5 37.8 44.8 0.0001
 Height, cm 165.3±9.5 163.5±9.7 165.6±9.5 0.0061
 Weight, kg 78.5±16.5 78.3±17.4 78.6±16.2 NS
 Obesity (BMI >30 kg/m2), % 21.3 22.9 20.9 0.0443
Blood pressure and selected laboratory values
 Systolic BP, mm Hg 129±21.0 128±23.4 129±20.3 NS
 Diastolic BP, mm Hg 74±12.8 70±13.6 75±12.4 0.0001
 Heart rate, bpm 88±17.3 89±18.9 88±16.9 NS
 Pulse pressure, mm Hg 55±19.8 59±19.7 54±17.2 0.0001
 Glycemia, mg/dL* 112 (98–136) 128 (108–165) 109 (97–129) 0.0001
 Creatinine, mg/dL* 0.8 (0.68–1.05) 1.1 (0.80–1.80) 0.80 (0.67–0.97) 0.0001
 Sodium, mg/dL 137±4.8 138±6.6 137±4.1 0.0062
 Potassium, mg/dL 4.1±0.6 4.3±0.69 4.1±0.52 0.0015
 Triglycerides, mg/dL* 121 (94–158) 121 (93–163) 121 (94–157) NS
Comorbidities
 Hypertension, % 50.9 70.7 45.5 0.0001
 Diabetes, % 19.1 28.2 16.6 0.0001
 COPD, % 7.0 12.6 5.5 0.0001
 CKD, % 6.0 12.5 4.2 0.0001
 Coronary heart disease, % 7.9 14.0 6.3 0.0001
 Heart failure, % 7.1 15.4 4.9 0.0001
 Stroke, % 7.7 14.1 6.0 0.0001
 Atrial fibrillation, % 11.1 21.6 8.3 0.0001
 Peripheral vascular disease, % 4.7 9.0 3.5 0.0001
 Arterial stiffness, % 36.0 43.7 33.9 0.0001
 Charlson Comorbidity Index 3.6±2.7 5.7±2.4 3.1±2.5 0.0001
Values are average (SD). BMI indicates body mass index; BP, blood pressure; CKD, chronic kidney disease; and COPD, chronic obstruc-
tive pulmonary disease.
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includes SBP as part of its definition. The extent that 
the predictive value of PP exceeds that of BP alone is a 
long-standing unresolved controversy.26–28
Several mechanisms may account for the role of AS in 
the COVID-19 pandemic. Older age has been invariably 
shown as the principal risk factor in the COVID-19. Aging 
is a process characterized by quantitative and qualita-
tive alterations of the immune system, with an increase 
in proinflammatory and a decrease in anti-inflammatory 
cytokines resulting in a state of chronic, low-grade 
inflammation often referred to as immunosenescence.29 
Furthermore, the COVID-19-related cytokine storm has 
been hypothesized to be the consequence of aging, 
leading to the coining of the term inflame-aging.30
On the contrary, although there is no unanimous con-
sensus on the causal association between systemic 
inflammation and cardiovascular events,31 several studies 
have fueled interest in vasculature properties and inflam-
matory molecules as surrogate markers of cardiovascu-
lar risk, with contradictory results.32–35 Hypertension is 
the strongest modifiable risk factor for cardiovascular 
disease worldwide, and low-grade inflammatory compo-
nents have repeatedly been identified in the pathophysi-
ology of hypertension.36,37 The characteristic features 
of hypertension include premature changes in vascular 
function and structure that can be demonstrated ear-
lier and are more severe than those predicted as part of 
the normal aging process, leading to the so-called early 
Table 3. Association of Selected Variables With All-Cause In-Hospital Mortality as Dependent 
Variable
Variable
Univariate analysis Multivariate analysis
OR (95% CI) P value ORadj (95% CI) P value
Age, tertiles
 <60.9 1  1  
 ≥60.9 and <76.3 5.3 (4.38–6.30) 0.0001 2.0 (1.56–2.44) 0.0001
 ≥76.3 20.5 (17.18–24.38) 0.0001 4.7 (3.77–5.97) 0.0001
Blood pressure treatment
 Normotensive subjects 1  1  
 Other than ACEIs/ARBs 3.5 (3.11–3.97) 0.0001 1.30 (1.13–1.50) 0.0001
 ACEIs 3.0 (2.63–3.36) 0.0001 1.62 (1.38–1.90) 0.0001
 ARBs 2.3 (2.07–2.64) 0.0001 1.21 (1.03–1.41) 0.0182
Charlson Comorbidity Index, tertiles
 <2 1  1  
 ≥2 and <5 11.4 (9.51–13.70) 0.0001 4.8 (3.82–6.02) 0.0001
 ≥5 28.6 (23.75–34.50) 0.0001 8.6 (6.72–10.90) 0.0001
Sex
 Female 1  1  
 Male 1.3 (1.16–1.38) 0.0001 1.6 (1.43–1.75) 0.0001
Arterial stiffness
 No 1  1  
 Yes 1.5 (1.39–1.65) 0.0001 1.27 (1.11–1.45) 0.0001
Use of ACE inhibitors
 No 1  1  
 Yes 1.1 (0.94–1.25) 0.30 0.56 (0.47–0.68) 0.0001
Use of ARBs
 No 1  1  
 Yes 0.86 (0.75–1.00) 0.050 0.56 (0.47–0.67) 0.0001
HF
 No 1  1  
 Yes 3.6 (3.09–4.10) 0.0001 1.24 (1.06–1.46) 0.0091
SBP at admission
 ≥120 and <140 1  1  
 <120 1.34 (1.21–1.49) 0.0001 1.48 (1.30–1.68) 0.0001
 ≥140 1.29 (1.16–1.44) 0.0001 0.82 (0.72–0.94) 0.0041
Univariate analysis and adjusted multivariate logistic regression model. ACE indicates angiotensin-converting enzyme; ARB, 
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vascular aging.38 What is more, AS has been claimed to 
precede incident hypertension39 and underlie the vicious 
circle of arteriosclerosis and hypertension.40 A variety 
of mechanisms may be responsible for the association 
between age, inflammation, hypertension, and AS, but 
there is a growing body of evidence that adverse remod-
eling through proinflammatory signaling secondary to the 
angiotensin II signaling cascade with aging is of para-
mount importance.41,42
The strengths of our study are the large number of 
participants, the use of a hard end point for analysis, and 
previous experience in handling databases by a scien-
tific society. Nevertheless, its retrospective design, the 
high proportion of White participants, the unknown real 
spread of COVID-19 among outpatients, the strict inclu-
sion of patients with COVID-19 requiring hospitalization, 
and the indirect estimation of AS mean that our results 
cannot be easily extrapolated to the general population.
PERSPECTIVES
In conclusion, assessment of simple hemodynamic vari-
ables such as SBP and PP at the very beginning of hos-
pitalization of patients with COVID-19 appears to have 
practical consequences on outcomes.
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